Most Viewed Articles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Most Viewed Articles

A Look into the Future: The Pharmaceutical Company of 2020

July 11, 2012

PTSM: Pharmaceutical Technology Sourcing and Management

How will the pharmaceutical company of 2020 be different from the pharmaceutical company of 2010? A look at emerging business models and the factors influencing the direction of the global pharmaceutical industry.

Biosimilars: Market Weaknesses and Strengths

July 11, 2012

PTSM: Pharmaceutical Technology Sourcing and Management

Biosimilars represent an emerging niche in the biopharmaceutical market, but how strong is their true potential?

Decades of Change for the Top Pharmaceutical Companies

July 11, 2012

PTSM: Pharmaceutical Technology Sourcing and Management

Tracking change from spinoffs of chemical companies to life-sciences powerhouses.

Congress Passes Generic Drug Act

July 10, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

On July 9, 2012, Congress passed the Generic Drug User Fee Act in an effort to expedite the process of bringing generic drugs to market. The Act authorizes the collection of user fees from generic-drug manufacturing companies for the first time in the industry's history.

ISPE Issues Guidance for Packaging, Labeling, and Warehousing Facilities

July 9, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

ISPE has issued a guidance that is intended to help companies meet cGMP requirements for packaging, labeling, and warehousing facilities and avoid problems such as product adulteration, product mix-up, label mix-up, and misbranding.

FDA Issues Draft Guidance on OTC Products that Contain Acetaminophen

July 3, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has issued a draft guidance on the labeling of OTC products that contain acetaminophen. The draft guidance would give manufacturers an alternative option to properly clarify the risk of liver damage in OTC acetaminophen-containing products.

GSK Agrees to $3 Billion Settlement with Justice Department

July 3, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline has agreed to plead guilty and pay $3 billion to resolve criminal and civil liability resulting from unlawful promotion of certain drugs, failure to report safety data, and alleged false price reporting practices.

Bristol-Myers Squibb Agrees to Acquire Amylin for $5.3 Billion

July 2, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Bristol-Myers Squibb has agreed to acquire the biopharmaceutical company Amylin Pharmaceuticals for a purchase price of $5.3 billion and an additional $1.7 billion for assuming Amylin's net debt and a contractual payment obligation to Eli Lilly based on Amylin's recently terminated agreement with Eli Lilly over the diabetes drug exenatide.

Atypical Visible Particles

July 2, 2012

Pharmaceutical Technology

An industry roundtable on how users and makers can best assess and manage black specks.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here